MedTrace Logo

Comparing Medical Body Composition Analyzer Seca mBCA 555 With Seca mBCA 515

NCT04030416 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-02-14

Study results available
· View outcomes & findings →

Summary

The mBCA 515 was compared to the gold standard methods MRI, DXA, ADP, D2O- and NaBr-dilution in previous clinical investigations (BCA-01, BCA-02, BCA-20) to generate prediction equations for calculating body composition (FFM, SMM, ECW, TBW and VAT) in different populations. Furthermore, normal ranges for body composition were generated based on the previous study BCA-03 conducted at the UKE.

The mBCA 555 is a new body composition analyzer measuring bioimpedance in standing position developed by seca.

In order to apply prediction equations and normal ranges from previous clinical investigations BCA-01, BCA-02, BCA-03 and BCA-20 to the new mBCA 555 it shall be compared to the mBCA 515.

Conditions

  • Bioelectrical Impedance Measurement of Healthy Adults

Sponsors & Collaborators

  • Seca GmbH & Co. Kg.

    lead INDUSTRY

Principal Investigators

  • Sven Peine, Dr. · Universitätsklinikum Hamburg-Eppendorf

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-20
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04030416 on ClinicalTrials.gov